- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05548270
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: David Helton
- Phone Number: 949-981-6442
- Email: dhelton@defenderpharma.com
Study Locations
-
-
California
-
Santa Monica, California, United States, 90404
- Santa Monica Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to provide written, informed consent prior to initiation of any study-related procedures, and ability in the opinion of the Investigator to understand and comply with all the requirements of the study, which includes abstaining from the use of prohibited medications.
- Male and female subjects ≥18 years of age.
- Susceptible to provocative motion as evidenced by at least three responses of "Frequently" from the Motion Sickness Susceptibility Questionnaire Short-Form (MSSQ-Short).
- Acceptable overall medical condition to be safely enrolled in and complete the study in the opinion of the Investigator.
- Ability to take intranasal medication.
- Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is 2 years postmenopausal), or females of child-bearing potential using an acceptable method of birth control (i.e., oral contraception, systemic [injectable or patch] contraception, double barrier methods, strict abstinence, condoms, diaphragm, spermicidal agents, cervical cap, copper intrauterine device, etc.) for a period of up to 30 days before dosing and for one month after dosing and must have a negative pregnancy test at screening.
Agree to adhere to the following lifestyle compliance considerations:
- Refrain from consumption of grapefruit and any substance containing grapefruit for 7 days prior to, during, and 7 days after study drug administration;
- Abstain from alcohol for 24 hours prior to the administration of study drug and throughout the ocean travel;
- Abstain from marijuana within the 7-day period prior to the Treatment Day and throughout Day 2.
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) negative test, confirmed by Food and Drug Administration (FDA) authorized COVID-19 test ≤ 7 days prior to study drug administration or no COVID 19 symptoms 10 days prior to study drug administration.
Exclusion Criteria:
- Nauseated prior to boarding.
- Mini-Mental State Examination score of <24.
Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential, who:
- Are or intend to become pregnant (including use of fertility drugs) during the study;
- Are nursing (female subjects only);
- Are not using an acceptable, highly effective method of contraception until all follow up procedures are complete.
- Known allergic reactions to scopolamine or other anticholinergics.
- Hospitalization or significant surgery requiring hospital admittance within the past 6 months.
- Treatment with another investigational product within the past 30 days.
- Donated blood or plasma or suffered significant blood loss within the past 30 days.
- Chronic nausea caused by conditions such as irritable bowel syndrome, gastroparesis, cyclic vomiting syndrome or any other cause.
Having any of the following medical conditions within the last 2 years or if any of the following medical conditions were experienced more than 2 years ago and are deemed as clinically significant by the Investigator:
- Significant gastrointestinal disorder, asthma, or seizure disorders;
- History of or current cardiovascular disease;
- History of or current vestibular disorders;
- History of or current narrow-angle glaucoma;
- History of or current urinary retention problems; or
- History of or current alcohol or drug abuse.
- Has had any prior nasal, nasal sinus, or nasal mucosa surgery.
Currently taking any of the following medication types within the specified washout period:
- Any form of scopolamine (including Transderm Scop®/washout 5 days;
- Belladonna alkaloids/washout 14 days;
- Antihistamines (including meclizine/washout 14 days;
- Tricyclic antidepressants/washout 14 days;
- Muscle relaxants/washout 4 days; or
- Nasal decongestants/washout 4 days.
- Has used marijuana within the 7-day period prior to the Treatment Day. (Note: this criterion will only be confirmed at Eligibility Confirmation, not at Recruitment and Screening, although heavy users of marijuana can be determined ineligible at Screening. All potential study subjects deemed eligible at Screening must be informed at that time that this requirement must be met at Eligibility Confirmation.).
- Unwilling or unable to follow the medication restrictions or unwilling to wash-out the use of restricted medications as noted in Exclusion Criterion #11.
- Subject participated in a previous study of DPI-386 Nasal Gel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo Nasal Gel (0.12 g)
|
Subjects will self-administer DPI-386 Nasal Gel or Placebo
|
Experimental: DPI-386
Each 0.12 gram of the gel contains0.2
mg of scopolamine HBr
|
Subjects will self-administer DPI-386 Nasal Gel or Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants Who Report no Vomiting Within 4 Hours or to end of voyage, whichever comes later after Receiving Study Drug and no Use of Rescue Treatment
Time Frame: 4 hours
|
Proportion of subjects who report no vomiting within 4 hours or to end of voyage, whichever comes later, after receiving study drug and no use of rescue treatment (e.g., antihistamine) within 4 hours or to end of voyage, whichever comes later, after receiving study drug (Complete Responders).
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to vomiting or use of rescue medication
Time Frame: 4 hours
|
4 hours
|
|
Proportion of subjects who did not have moderate or severe nausea, which is defined as those subjects who report no moderate and severe nausea within 4 hours after receiving study drug and who did not use rescue treatment
Time Frame: 4 hours
|
Proportion of subjects who did not have moderate or severe nausea, which is defined as those subjects who report no moderate and severe nausea within 4 hours after receiving study drug and who did not use rescue treatment (e.g., antihistamine) within 4 hours after receiving study drug.
|
4 hours
|
Proportion of subjects who did not have nausea, which is defined as those subjects who report no nausea within 4 hours after receiving study drug and who did not use rescue treatment
Time Frame: 4 hours
|
Proportion of subjects who did not have nausea, which is defined as those subjects who report no nausea within 4 hours after receiving study drug and who did not use rescue treatment (e.g., antihistamine) within 4 hours after receiving study drug.
|
4 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Helton, Defender Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Vomiting
- Motion Sickness
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Antiemetics
- Gastrointestinal Agents
- Adjuvants, Anesthesia
- Mydriatics
- Scopolamine
Other Study ID Numbers
- DPI-386-MS-33
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motion Sickness
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness, Space | Motion Simulation | Parabolic FlightUnited States
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Faisal_Karmali@MEEI.HARVARD.EDUMassachusetts Institute of Technology; National Space Biomedical Research InstituteCompleted
-
Naval Aeromedical Research Unit, DaytonUnknownPrevention of Nausea Associated With Motion Sickness | Treatment of Nausea Associated With Motion SicknessUnited States
-
Wingate Institute of NeurogastroenterologyCompletedVisually Induced Motion Sickness in Healthy VolunteersUnited Kingdom
-
University Hospital, CaenCompleted
-
United States Army Aeromedical Research LaboratoryAlabama College of Osteopathic Medicine; Department of Aviation Medicine, U...CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Dartmouth-Hitchcock Medical CenterRecruiting
-
Vanda PharmaceuticalsRecruitingMotion SicknessUnited States
Clinical Trials on DPI-386 Nasal Gel
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Repurposed Therapeutics, Inc.Defender Pharmaceuticals, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness, Space | Motion Simulation | Parabolic FlightUnited States
-
Naval Aeromedical Research Unit, DaytonUnknownPrevention of Nausea Associated With Motion Sickness | Treatment of Nausea Associated With Motion SicknessUnited States
-
Acerus Pharmaceuticals CorporationCompletedFemale Sexual DysfunctionUnited States
-
Destiny Pharma PlcCompletedStaphylococcus Aureus InfectionUnited Kingdom
-
VA Office of Research and DevelopmentRecruiting